Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication
(2017) In Proceedings of the National Academy of Sciences of the United States of America 114(25). p.6444-6449- Abstract
The aggregation of the amyloid β peptide (Aβ) into amyloid fibrils is a defining characteristic of Alzheimer's disease. Because of the complexity of this aggregation process, effective therapeutic inhibitors will need to target the specific microscopic steps that lead to the production of neurotoxic species. We introduce a strategy for generating fibril-specific antibodies that selectively suppress fibril-dependent secondary nucleation of the 42-residue form of A (A42). We target this step because it has been shown to produce the majority of neurotoxic species during aggregation of A42. Starting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage approach that we describe includes (i) selection... (More)
The aggregation of the amyloid β peptide (Aβ) into amyloid fibrils is a defining characteristic of Alzheimer's disease. Because of the complexity of this aggregation process, effective therapeutic inhibitors will need to target the specific microscopic steps that lead to the production of neurotoxic species. We introduce a strategy for generating fibril-specific antibodies that selectively suppress fibril-dependent secondary nucleation of the 42-residue form of A (A42). We target this step because it has been shown to produce the majority of neurotoxic species during aggregation of A42. Starting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage approach that we describe includes (i) selection of scFvs with high affinity for A42 fibrils after removal of scFvs that bind A42 in its monomeric form; (ii) ranking, by surface plasmon resonance affinity measurements, of the resulting candidate scFvs that bind to the A42 fibrils; and (iii) kinetic screening and analysis to find the scFvs that inhibit selectively the fibril-catalyzed secondary nucleation process in A42 aggregation. By applying this approach, we have identified four scFvs that inhibit specifically the fibril-dependent secondary nucleation process. Our method also makes it possible to discard antibodies that inhibit elongation, an important factor because the suppression of elongation does not target directly the production of toxic oligomers and may even lead to its increase. On the basis of our results, we suggest that the method described here could form the basis for rationally designed immunotherapy strategies to combat Alzheimer's and related neurodegenerative diseases.
(Less)
- author
- organization
- publishing date
- 2017-06-20
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer, Antibody, Drug development, Inhibitor, Self-assembly
- in
- Proceedings of the National Academy of Sciences of the United States of America
- volume
- 114
- issue
- 25
- pages
- 6 pages
- publisher
- National Academy of Sciences
- external identifiers
-
- scopus:85021181906
- pmid:28584111
- wos:000403687300022
- ISSN
- 0027-8424
- DOI
- 10.1073/pnas.1700407114
- language
- English
- LU publication?
- yes
- id
- da1b124e-0f97-42d7-955d-d8fef1eaac3e
- date added to LUP
- 2017-07-11 14:33:58
- date last changed
- 2024-06-10 22:35:13
@article{da1b124e-0f97-42d7-955d-d8fef1eaac3e,
abstract = {{<p>The aggregation of the amyloid β peptide (Aβ) into amyloid fibrils is a defining characteristic of Alzheimer's disease. Because of the complexity of this aggregation process, effective therapeutic inhibitors will need to target the specific microscopic steps that lead to the production of neurotoxic species. We introduce a strategy for generating fibril-specific antibodies that selectively suppress fibril-dependent secondary nucleation of the 42-residue form of A (A42). We target this step because it has been shown to produce the majority of neurotoxic species during aggregation of A42. Starting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage approach that we describe includes (i) selection of scFvs with high affinity for A42 fibrils after removal of scFvs that bind A42 in its monomeric form; (ii) ranking, by surface plasmon resonance affinity measurements, of the resulting candidate scFvs that bind to the A42 fibrils; and (iii) kinetic screening and analysis to find the scFvs that inhibit selectively the fibril-catalyzed secondary nucleation process in A42 aggregation. By applying this approach, we have identified four scFvs that inhibit specifically the fibril-dependent secondary nucleation process. Our method also makes it possible to discard antibodies that inhibit elongation, an important factor because the suppression of elongation does not target directly the production of toxic oligomers and may even lead to its increase. On the basis of our results, we suggest that the method described here could form the basis for rationally designed immunotherapy strategies to combat Alzheimer's and related neurodegenerative diseases.</p>}},
author = {{Munke, Anna and Persson, Jonas and Weiffert, Tanja and De Genst, Erwin J. and Meisl, Georg and Arosio, Paolo and Carnerup, Anna and Dobson, Christopher M and Vendruscolo, Michele and Knowles, Tuomas P J and Linse, Sara}},
issn = {{0027-8424}},
keywords = {{Alzheimer; Antibody; Drug development; Inhibitor; Self-assembly}},
language = {{eng}},
month = {{06}},
number = {{25}},
pages = {{6444--6449}},
publisher = {{National Academy of Sciences}},
series = {{Proceedings of the National Academy of Sciences of the United States of America}},
title = {{Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication}},
url = {{http://dx.doi.org/10.1073/pnas.1700407114}},
doi = {{10.1073/pnas.1700407114}},
volume = {{114}},
year = {{2017}},
}